Alterity Therapeutics Limited (ASX:ATH)
Australia · Delayed Price · Currency is AUD 0.0090
0.00 (0.00%)
May 29, 2026, 2:37 PM AEST
Alterity Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Other Revenue | 6.64 | 5.44 | 4.02 | 3.92 | 5.12 | 4.34 |
| 6.64 | 5.44 | 4.02 | 3.92 | 5.12 | 4.34 | |
Revenue Growth (YoY) | 78.18% | 35.32% | 2.63% | -23.56% | 18.06% | - |
Cost of Revenue | 0.16 | 0.13 | 0.21 | 0.29 | 0.36 | 0.36 |
Gross Profit | 6.47 | 5.31 | 3.8 | 3.63 | 4.76 | 3.98 |
Selling, General & Admin | 7.61 | 5.48 | 4.76 | 5.06 | 5.51 | 6.94 |
Research & Development | 16.53 | 14.4 | 18.64 | 13.2 | 14.75 | 12.28 |
Other Operating Expenses | 0.22 | 0.09 | 0.01 | 0.03 | 0 | 0 |
Operating Expenses | 24.04 | 19.97 | 23.41 | 18.27 | 20.26 | 19.16 |
Operating Income | -17.56 | -14.66 | -19.61 | -14.64 | -15.5 | -15.18 |
Interest & Investment Income | 1.24 | 0.45 | 0.27 | 0.02 | 0 | 0.02 |
Currency Exchange Gain (Loss) | -0.02 | 0.26 | 0.26 | 0.92 | 2.72 | -0.3 |
Other Non Operating Income (Expenses) | -0.33 | -0.33 | - | - | - | - |
EBT Excluding Unusual Items | -16.66 | -14.28 | -19.08 | -13.7 | -12.78 | -15.45 |
Other Unusual Items | 1.98 | 1.98 | - | - | - | 0.15 |
Pretax Income | -14.46 | -12.08 | -19.08 | -13.7 | -12.78 | -15.31 |
Income Tax Expense | 0.13 | 0.07 | 0.05 | 0.1 | 0.07 | - |
Net Income | -14.59 | -12.15 | -19.12 | -13.81 | -12.85 | -15.31 |
Net Income to Common | -14.59 | -12.15 | -19.12 | -13.81 | -12.85 | -15.31 |
Shares Outstanding (Basic) | 8,830 | 6,397 | 3,649 | 2,428 | 2,406 | 1,697 |
Shares Outstanding (Diluted) | 8,830 | 6,397 | 3,649 | 2,428 | 2,406 | 1,697 |
Shares Change (YoY) | 74.72% | 75.31% | 50.29% | 0.91% | 41.79% | 89.62% |
EPS (Basic) | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
EPS (Diluted) | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
Free Cash Flow | -13.71 | -11.45 | -12.61 | -20.04 | -12.43 | -17.34 |
Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 |
Gross Margin | 97.55% | 97.66% | 94.67% | 92.72% | 92.88% | 91.70% |
Operating Margin | -264.66% | -269.57% | -487.82% | -373.72% | -302.56% | -349.77% |
Profit Margin | -219.85% | -223.35% | -475.79% | -352.54% | -250.75% | -352.78% |
Free Cash Flow Margin | -206.62% | -210.54% | -313.78% | -511.78% | -242.54% | -399.59% |
EBITDA | -17.55 | -14.63 | -19.57 | -14.6 | -15.48 | -15.16 |
EBITDA Margin | -264.46% | -269.05% | - | - | - | - |
D&A For EBITDA | 0.01 | 0.03 | 0.04 | 0.04 | 0.02 | 0.02 |
EBIT | -17.56 | -14.66 | -19.61 | -14.64 | -15.5 | -15.18 |
EBIT Margin | -264.66% | -269.57% | - | - | - | - |